Australian Fibrosis Pioneers Merge Ahead Of Financing

19 Dec 2024

Certa and OccuRx both came out of Fibrotech and are now joining forces to advance asengeprast as a potential therapy for scleroderma and focal segmental glomerulosclerosis.

Australia handshake flag agreement deal — • Source: Alamy

Australian biotechs Certa Therapeutics and OccuRx are combining their assets under one company in a bid to become a leading player in the fibrotic diseases space.

Certa’s acquisition of fellow Melbourne-based firm OccuRx brings together two outfits that have a shared focus on targeting GPR68, which they claim is a “master switch of fibrosis

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

14 May 2025

• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

14 May 2025

• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

14 May 2025

• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.